Nevirapine Amarox (Nevirapine)

Nevirapine is a non‑nucleoside reverse transcriptase inhibitor used in the management of HIV‑1 infection, typically as part of combination antiretroviral therapy.

• HIV‑1 infection (treatment): reduces plasma HIV RNA levels and improves immune function.
• Combination antiretroviral therapy (HAART): contributes to overall viral suppression when used with other antiretrovirals.
• Treatment‑experienced HIV‑1 infection: provides an option for patients with resistance to other agents.

• Nevirapine binds to a non‑nucleoside site on the HIV‑1 reverse transcriptase enzyme, inducing a conformational change that prevents the enzyme from transcribing viral RNA into DNA. This inhibition blocks the replication cycle of HIV, leading to decreased viral load and restoration of immune competence.

Nevirapine may cause a range of adverse reactions, from mild to severe. Monitoring for side effects is essential during therapy.

Common Side Effects

• Rash: mild to moderate skin eruptions.
• Nausea: occasional gastrointestinal discomfort.
• Fatigue: feeling of tiredness or weakness.
• Headache: transient cranial pain.
• Dizziness: light‑headed sensation.
• Abdominal pain: mild stomach discomfort.

Serious or Rare Side Effects

• Stevens‑Johnson syndrome: severe skin reaction requiring immediate discontinuation.
• Hepatic failure: signs of liver toxicity such as jaundice.
• Severe hypersensitivity: systemic allergic response.
• Neutropenia: marked reduction in white blood cells.
• Hepatotoxicity: elevated liver enzymes indicating liver injury.

Nevirapine requires careful monitoring due to potential hepatic and dermatologic risks.

• Liver function monitoring: assess transaminases before and during treatment.
• Pre‑existing hepatic disease: avoid or use with caution in severe liver impairment.
• Rash management: discontinue if severe or progressing to Stevens‑Johnson syndrome.
• Pregnancy considerations: safety data are limited; evaluate risk‑benefit.
• Drug resistance: avoid monotherapy to prevent resistance development.
• Store below 25°C: keep in the original pack, protect from moisture.

Nevirapine interacts with several agents that can alter its plasma levels or increase toxicity.

Major Interactions (Avoid)

• Rifampin: induces metabolism, reducing nevirapine exposure.
• St. John’s wort: strong enzyme inducer, markedly lowers drug levels.
• Protease inhibitors (e.g., ritonavir): can increase nevirapine concentrations and risk of hepatotoxicity.
• Carbamazepine: induces metabolism, decreasing efficacy.

Moderate Interactions (Monitor Closely)

• Azole antifungals (e.g., fluconazole): may raise nevirapine levels.
• Macrolide antibiotics (e.g., erythromycin): modest increase in exposure.
• Oral contraceptives: nevirapine may reduce hormonal efficacy.
• Warfarin: potential alteration of anticoagulant effect, monitor INR.